Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Gujarat government...

    Gujarat government announces Biotechnology Policy

    Written by supriya kashyap kashyap Published On 2016-12-28T11:57:06+05:30  |  Updated On 28 Dec 2016 11:57 AM IST
    Gujarat government announces Biotechnology Policy

    Gandhinagar : With an aim to establish Gujarat as a preferred destination for manufacturing of biotechnology products, the state government announced its Biotechnology Policy-2016.


    The policy has various incentives for investors who are keen to set up their units in the state.


    Under the policy, the state government would provide capital subsidy up to Rs 25 crore on the total investment for developing a Biotechnology (BT) Park, said Gujarat Deputy Chief Minister Nitin Patel while announcing the policy.


    In addition, the developer of such park will be eligible for 100 per cent reimbursement of stamp duty paid on sale or lease of the land for setting such park, stated the policy document.


    BT Park developer will be given 100 per cent reimbursement for electricity duty paid for a period of five years, it added.


    For individual BT manufacturing units having gross fixed capital investment (GFCI) up to Rs 50 crore, government would give capital subsidy up to Rs 10 per cent of the GFCI with a ceiling of Rs 5 crore.


    Further, BT units with borrowings up to Rs 50 crore shall be entitled to an interest subsidy at the rate of 5 per cent with a ceiling of 2.5 crore per annum, the document added.


    To encourage new start-ups in this sector, government would give 100 per cent reimbursement of stamp duty paid on sale or lease of the land for setting such start-up, it added.


    According to Patel, governments aim is to make Gujarat number one in Biotechnology sector by attracting new investment.


    "At present, there are 175 BT units in Gujarat having total turnover of Rs 4,500 crore per annum. We are on number three spot in India. Our aim behind bringing this policy is to take this turnover to Rs 15,000 crore within next three-four years and make Gujarat number one in this sector," said Patel.

    BiotechnologyBiotechnology PolicyBiotechnology Policy-2016GFCIgross fixed capital investmentGujarat governmentNitin Patelpolicy
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok